Shanghai Pharmaceuticals Holding Co Ltd
SSE:601607

Watchlist Manager
Shanghai Pharmaceuticals Holding Co Ltd Logo
Shanghai Pharmaceuticals Holding Co Ltd
SSE:601607
Watchlist
Price: 21.23 CNY -0.66%
Market Cap: 60.5B CNY
Have any thoughts about
Shanghai Pharmaceuticals Holding Co Ltd?
Write Note

Operating Margin
Shanghai Pharmaceuticals Holding Co Ltd

3.1%
Current
4%
Average
4.2%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
3.1%
=
Operating Profit
8.5B
/
Revenue
272.4B

Operating Margin Across Competitors

Country CN
Market Cap 60.5B CNY
Operating Margin
3%
Country US
Market Cap 77.7B USD
Operating Margin
1%
Country US
Market Cap 48.6B USD
Operating Margin
1%
Country US
Market Cap 48.4B USD
Operating Margin
1%
Country US
Market Cap 30.3B USD
Operating Margin
1%
Country US
Market Cap 9.3B USD
Operating Margin
5%
Country CN
Market Cap 65.2B CNY
Operating Margin
10%
Country KR
Market Cap 12.2T KRW
Operating Margin
9%
Country CN
Market Cap 64.3B HKD
Operating Margin
4%
Country IT
Market Cap 5.5B EUR
Operating Margin
12%
Country DE
Market Cap 5B EUR
Operating Margin
1%
No Stocks Found

Shanghai Pharmaceuticals Holding Co Ltd
Glance View

Market Cap
60.5B CNY
Industry
Health Care

Shanghai Pharmaceuticals Holding Co Ltd, a key player in China's healthcare sector, emerged from its roots in the early 1990s to become one of the largest pharmaceutical companies in the country. It operates in two main segments: pharmaceutical manufacturing and distribution. With a strong portfolio of generic and branded medications, the company leverages its extensive distribution network to reach hospitals and pharmacies across China. Shanghai Pharmaceuticals focuses on innovative drug development and has made significant strides in research, particularly in oncology and high-demand therapeutic areas, positioning itself well for growth in a rapidly evolving market. For investors, Shanghai Pharmaceuticals represents a compelling opportunity, not only due to its robust domestic market but also its potential for international expansion. The company's commitment to R&D, alongside strategic partnerships with global pharmaceutical firms, underscores its forward-thinking approach. Additionally, as China's healthcare reforms push for improved access to medicines, Shanghai Pharmaceuticals stands to benefit from increased demand. With a seasoned management team and a solid track record of consistent revenue growth, investors looking for exposure in the burgeoning Asian pharmaceutical landscape may find Shanghai Pharmaceuticals an attractive addition to their portfolios.

Intrinsic Value
47 CNY
Undervaluation 55%
Intrinsic Value
Price

See Also

Discover More
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
3.1%
=
Operating Profit
8.5B
/
Revenue
272.4B
What is the Operating Margin of Shanghai Pharmaceuticals Holding Co Ltd?

Based on Shanghai Pharmaceuticals Holding Co Ltd's most recent financial statements, the company has Operating Margin of 3.1%.